

Company Overview

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immunology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation of Dexmedetomidine in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immunology agents.

BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials

Mar 19 2020, 7:15 AM EDT

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

Mar 9 2020, 7:00 AM EDT

BioXcel Therapeutics to Host Fourth Quarter and Full Year 2019 Operating and Financial Results Conference Call and Webcast

Mar 2 2020, 7:00 AM EST

Stock Overview

Symbol	BTAI
Exchange	Nasdaq
Market Cap	493.06m
Last Price	\$24.43
52-Week	\$3.76 - \$43.6297

03/27/2020 04:00 PM EDT

Investor Relations

Janhavi Mohite
T: 646-536-7026
jmohite@theruthgroup.com

Management Team

Vimal Mehta, Ph.D.

Chief Executive Officer & Founder

Frank D. Yocca, Ph.D.

Chief Scientific Officer

Vincent J.O'Neill M.D.

Senior Vice President & Chief Medical Officer

Richard I. Steinhart

Chief Financial Officer & Vice President

Chetan Lathia Ph.D.

Senior Vice President and Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs

BioXcel Therapeutics, Inc.

555 Long Wharf Drive
12th Floor
New Haven, CT 06511
United States

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.